Pharmacology News and Research

Latest Pharmacology News and Research

New ways to tackle diabetes

According to a new analysis from UK, a diet rich in green leafy vegetables may reduce the risk of developing diabetes. The inference was drawn from six studies which looked into fruit and vegetable intake and found that only food including spinach and cabbage was found to have a significant positive effect. The findings were published in the British Medical Journal (BMJ).

19 Aug 2010

PAREXEL International launches temperature recording solution optimized for clinical trial supply process

PAREXEL International Corporation, a leading global biopharmaceutical services organization, today announced that it has introduced an integrated temperature recording solution for study drug transportation as part of its expanded Clinical Logistics Services.

From Parexel 19 Aug 2010

Deficiencies in DNA loop formation can cause multiple diseases: Research

The genes that are responsible for maintaining each cell type form DNA loops that link control elements for these genes. This surprising genome structure is generated and reinforced by two essential protein complexes that bridge the loops and contribute to proper gene regulation.

19 Aug 2010

Study finds factor behind alcohol use disorder after liver transplantation

Patients who receive a liver transplant due to alcoholic liver disease need to demonstrate periods of abstinence and often attend addiction treatment before transplantation. However, alcohol use disorders can recur, as can other diseases requiring transplantation, and thus alcohol use after liver transplantation is not uncommon.

19 Aug 2010

Intellect Neurosciences locks database of OXIGON Phase 1b clinical trial for Alzheimer's disease

Intellect Neurosciences, Inc. a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced that it has locked the database of the Company's Phase 1b clinical trial for its lead Alzheimer's candidate, OXIGON™ (OX1).

18 Aug 2010

NACTN receives grant to expand spinal cord injury research

The United States Department of Defense (DoD) awarded the Christopher & Dana Reeve Foundation a $5.4 million grant to support the expansion of translational research to find treatments for military men and women with spinal cord injuries.

18 Aug 2010

Scientist suggests emodin can reduce impact of type 2 diabetes

Emodin, a natural product that can be extracted from various Chinese herbs including Rheum palmatum and Polygonum cuspidatum, shows promise as an agent that could reduce the impact of type 2 diabetes. Findings published in this month's edition of the British Journal of Pharmacology show that giving emodin to mice with diet-induced obesity lowered blood glucose and serum insulin, improved insulin resistance and lead to more healthy levels of lipid in the blood. It also decreased body weight and reduced central fat mass.

18 Aug 2010

Springer to publish ASENT's Neurotherapeutics journal

Beginning in 2011, Springer will publish Neurotherapeutics, the official Journal of the American Society for Experimental NeuroTherapeutics (ASENT). With the switch to Springer, Neurotherapeutics will change its format of publishing review articles only to offering original research articles as well. The journal achieved a debut Impact Factor of 5.38 in 2009, placing it in the top quartile of journals in both the Neurosciences and Pharmacology & Pharmacy categories.

17 Aug 2010

Enrollment open in Phase I clinical study of Morphotek's MORAb-028 for advanced melanoma

Morphotek, Inc., a subsidiary of Eisai Inc., announced today that the John Wayne Cancer Institute in Santa Monica, California has opened enrollment in a Phase I clinical study with MORAb-028 in patients with advanced melanoma.

16 Aug 2010

Researchers develop screening tool to observe nanoparticle reaction inside the body

Researchers at North Carolina State University have developed a method for predicting the ways nanoparticles will interact with biological systems - including the human body. Their work could have implications for improved human and environmental safety in the handling of nanomaterials, as well as applications for drug delivery.

16 Aug 2010

NewCardio second-quarter net loss decreases to $1.5 million

NewCardio, Inc., a cardiac diagnostic technology provider, today announced financial results for the second quarter ended June 30, 2010.

13 Aug 2010

Evotec revenues for first-half of 2010 increase 33% to € 25.0 m

Evotec AG today reported financial results and corporate updates for the first half of 2010.

12 Aug 2010

Ohio State University procures IonFlux 16 high throughput automated patch clamp instrument

Fluxion Biosciences, Inc. announced today that the Ohio State University Department of Pharmacology has purchased the IonFlux 16, the first high throughput automated patch clamp instrument of its kind geared towards the academic researcher. The IonFlux instrument will enable large scale pharmacology experiments on this group's nAChR targets, which previously were not feasible using a manual patch clamp rig.

From Fluxion Biosciences 11 Aug 2010

Silence Therapeutics receives patent for RNA silencing method

Silence Therapeutics plc announces the issuance of United States patent 7,772,203, titled "Methods and Compositions for Controlling Efficacy of RNA Silencing," by the United States Patent and Trademark Office (USPTO). The issued patent generally claims methods of enhancing RNA silencing with a double stranded RNA interference (RNAi) agent. The patent's RNA silencing method claims include coverage for the administering of a pharmaceutical composition containing short interfering RNA (siRNA), micro RNA (miRNA), pre-miRNA or short hairpin (shRNA) molecules. Silence believes the proprietary structural modification techniques covered in this patent will play a key role in increasing the potential therapeutic efficacy of RNAi therapeutics.

11 Aug 2010

AssureRx Health achieves CAP accreditation for laboratory pharmacogenetic testing services

AssureRx Health, Inc. today announced that it has received accreditation from the College of American Pathologists for the delivery of high-quality, reliable laboratory pharmacogenetic testing services that meet or exceed regulatory laboratory standards and ensure commitment to patient care.

11 Aug 2010

PAREXEL International fourth-quarter consolidated service revenue increases 19.4% to $295.3 million

PAREXEL International Corporation today reported financial results for the fourth quarter and fiscal year ended June 30, 2010.

From Parexel 10 Aug 2010

Scientific paper explains impact of visual cycle modulation in neurovascular retinopathy

Acucela, a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, announced today that a scientific paper co-authored by Ryo Kubota, M.D., Ph.D., chairman, president and chief executive officer of Acucela, has been published in Experimental Eye Research. The paper, "Visual Cycle Modulation in Neurovascular Retinopathy" was also co-authored by scientists from Children's Hospital and Harvard Medical School in Boston and demonstrates for the first time the impact of treatment with a visual cycle modulator (VCM) on retinopathy in an immature eye.

10 Aug 2010

Loyola University forms new institute for molecular level disease research

Loyola University Chicago Stritch School of Medicine has formed a new research institute dedicated to understanding the molecular causes of cancer, autoimmune disorders, cardiovascular disease and several other illnesses.

10 Aug 2010

Scientist to research on molecular machinery of breast cancer

Someone in the world is diagnosed with breast cancer every 23 seconds. It is the leading cause of cancer death worldwide among women and approximately 456,000 die from the disease each year. At The University of Texas Health Science Center at Houston (UTHealth), a scientist is taking aim at the molecular machinery behind this disease.

10 Aug 2010

EpiCept second-quarter net loss decreases to $4.9 million

EpiCept Corporation today announced operating and financial results for the three and six months ended June 30, 2010, and provided an update with respect to the Company's key business initiatives.

7 Aug 2010